NeuroAiD is safe and well-tolerated
The safety of NeuroAiD is well established in ischemic stroke patients in post-acute and chronic stages. All the studies made on NeuroAiD were comparative to placebo. There is no better comparator to assess the safety of a product.
• No interaction with the standard treatments used in post-stroke management.1,3
• No change in cardiac, haematological, haemostatic, biochemical parameters.3,4
• No serious side effects associated with NeuroAiD during treatment1. Rare, transient and mild side effects (gastrointestinal symptoms) were reported1. These are usually resolved by halving the dose over the first week of treatment.
• No increase in delayed adverse events after treatment completion and a follow-up of 2 years.2,5
Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebocontrolled, randomized study. Stroke 2013a;44:2093-2100
NeuroAiD is safe as an add-on treatment in neurological recovery.
To date, no drug interactions with NeuroAiD have been reported.
NeuroAiD should be taken in addition to preventive treatments of cardiovascular risk factors commonly prescribed after a stroke; these typically include antiplatelet, antihypertensive, and cholesterol-lowering drugs, among others such as anti-diabetics.
Systematic clinical trials have shown that NeuroAiD does not have any interaction with aspirin. Patients taking NeuroAiD with anticoagulants have reported no impact on their INR (International Normalized Ratio). Nevertheless, it is recommended to monitor INR when NeuroAiD is initiated.
NeuroAiD is manufactured in China and in the Republic of Singapore under the international standards of Good Manufacturing Practice (GMP).
The GMP standards are applied to procedures in manufacturing dietary supplements, including approval of raw materials, production and process controls, laboratory testing, and product packaging, labeling, and distribution. These processes are regularly audited by independent health authorities.
The ingredients are carefully selected in compliance with the Chinese Pharmacopoeia’s standards. Every batch of NeuroAiD is analyzed thoroughly by third-party independent laboratories to confirm compliance with international standards, ensuring utmost ensuring utmost security of NeuroAiD use.
1. Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke 2013a;44:2093-2100
2. Venketasubramanian N, et al. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases 2015;39:309-318.
3. Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases 2010;30:1-6.
4. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases 2008;25:450-456.
5. Shahripour RB, et al. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med 2014;20(11):812-817.